These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 23194655)

  • 1. Glycine reuptake inhibition as a new therapeutic approach in schizophrenia: focus on the glycine transporter 1 (GlyT1).
    Chue P
    Curr Pharm Des; 2013; 19(7):1311-20. PubMed ID: 23194655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study.
    Umbricht D; Alberati D; Martin-Facklam M; Borroni E; Youssef EA; Ostland M; Wallace TL; Knoflach F; Dorflinger E; Wettstein JG; Bausch A; Garibaldi G; Santarelli L
    JAMA Psychiatry; 2014 Jun; 71(6):637-46. PubMed ID: 24696094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia.
    Tsai G; Lane HY; Yang P; Chong MY; Lange N
    Biol Psychiatry; 2004 Mar; 55(5):452-6. PubMed ID: 15023571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of glycine transporter 1: The yellow brick road to new schizophrenia therapy?
    Singer P; Dubroqua S; Yee BK
    Curr Pharm Des; 2015; 21(26):3771-87. PubMed ID: 26205290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitors of GlyT1 affect glycine transport via discrete binding sites.
    Mezler M; Hornberger W; Mueller R; Schmidt M; Amberg W; Braje W; Ochse M; Schoemaker H; Behl B
    Mol Pharmacol; 2008 Dec; 74(6):1705-15. PubMed ID: 18815213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glutamate-based therapeutic approaches: inhibitors of glycine transport.
    Lechner SM
    Curr Opin Pharmacol; 2006 Feb; 6(1):75-81. PubMed ID: 16376148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pro-cognitive effects of the GlyT1 inhibitor Bitopertin in rodents.
    Deiana S; Hauber W; Munster A; Sommer S; Ferger B; Marti A; Schmid B; Dorner-Ciossek C; Rosenbrock H
    Eur J Pharmacol; 2022 Nov; 935():175306. PubMed ID: 36183855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progress in the preparation and testing of glycine transporter type-1 (GlyT1) inhibitors.
    Lindsley CW; Wolkenberg SE; Kinney GG
    Curr Top Med Chem; 2006; 6(17):1883-96. PubMed ID: 17017963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycine transporter-1: a new potential therapeutic target for schizophrenia.
    Hashimoto K
    Curr Pharm Des; 2011; 17(2):112-20. PubMed ID: 21355838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycine transporter 1 as a potential therapeutic target for schizophrenia-related symptoms: evidence from genetically modified mouse models and pharmacological inhibition.
    Möhler H; Boison D; Singer P; Feldon J; Pauly-Evers M; Yee BK
    Biochem Pharmacol; 2011 May; 81(9):1065-77. PubMed ID: 21333635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allosteric modulation of NMDA receptor via elevation of brain glycine and D-serine: the therapeutic potentials for schizophrenia.
    Yang CR; Svensson KA
    Pharmacol Ther; 2008 Dec; 120(3):317-32. PubMed ID: 18805436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rescue of hippocampal LTP and learning deficits in a rat model of psychosis by inhibition of glycine transporter-1 (GlyT1).
    Manahan-Vaughan D; Wildförster V; Thomsen C
    Eur J Neurosci; 2008 Oct; 28(7):1342-50. PubMed ID: 18973561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycine transporters in schizophrenia. A new hope or informational noise?
    Zakowicz P; Pawlak J
    Psychiatr Pol; 2022 Apr; 56(2):217-228. PubMed ID: 35988070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design of potent GlyT1 inhibitors: in vitro and in vivo profiles.
    Bridges TM; Williams R; Lindsley CW
    Curr Opin Mol Ther; 2008 Dec; 10(6):591-601. PubMed ID: 19051137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of striatal dopamine release by glycine transport inhibitors.
    Javitt DC; Hashim A; Sershen H
    Neuropsychopharmacology; 2005 Apr; 30(4):649-56. PubMed ID: 15688094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycine transport inhibitors for the treatment of schizophrenia: symptom and disease modification.
    Javitt DC
    Curr Opin Drug Discov Devel; 2009 Jul; 12(4):468-78. PubMed ID: 19562643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of a glycine transporter 1 inhibitor TASP0315003 in animal models of cognitive dysfunction and negative symptoms of schizophrenia.
    Chaki S; Shimazaki T; Karasawa J; Aoki T; Kaku A; Iijima M; Kambe D; Yamamoto S; Kawakita Y; Shibata T; Abe K; Okubo T; Sekiguchi Y; Okuyama S
    Psychopharmacology (Berl); 2015 Aug; 232(15):2849-61. PubMed ID: 25869273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glycine transporter 1 inhibitors and modulation of NMDA receptor-mediated excitatory neurotransmission.
    Sur C; Kinney GG
    Curr Drug Targets; 2007 May; 8(5):643-9. PubMed ID: 17504107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of D-cycloserine and sarcosine on in vivo frontal neural activity in a schizophrenia-like model.
    Yao L; Wang Z; Deng D; Yan R; Ju J; Zhou Q
    BMC Psychiatry; 2019 Oct; 19(1):314. PubMed ID: 31653237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycine Signaling in the Framework of Dopamine-Glutamate Interaction and Postsynaptic Density. Implications for Treatment-Resistant Schizophrenia.
    de Bartolomeis A; Manchia M; Marmo F; Vellucci L; Iasevoli F; Barone A
    Front Psychiatry; 2020; 11():369. PubMed ID: 32477178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.